Medicare Drug Price Negotiations: What’s at Stake for Seniors
The Trump administration is working on lowering prices for 15 common drugs included in Medicare coverage. The government estimates this action will cut spending on these medications by about 44%, which translates to around $12 billion. But, will this really lead to savings for seniors?
It’s a bit complicated. Medicare enrollees already have some protections in place with caps on their drug costs. The Centers for Medicare and Medicaid Services (CMS) announced that the new pricing could save about $685 million for the 55 million individuals enrolled in Medicare Part D drug plans.
The savings each person sees might differ based on whether they take one or more of these newly discounted medications, and whether they hit their annual spending limits. With approximately 5.3 million individuals using these drugs, it averages out to about $129 saved per Medicare enrollee.
CMS didn’t immediately provide comments regarding the expected individual savings under the new rate plan.
This price reduction was made possible by the Inflation Control Act, which allows negotiations for some of Medicare’s priciest drugs. Before this law took effect in 2022, Medicare couldn’t negotiate pricing with drug companies to make medications more affordable for beneficiaries.
The price reductions for these 15 drugs are set to become effective in 2027 for medications purchased through CMS under the Medicare Part D prescription plan. The discounts are reported to vary between 38% and 85% off the listed prices.
Among the well-known medications affected are Novo Nordisk’s Ozempic and Wegovy, both recognized for managing diabetes and promoting weight loss. Other drugs on the list treat prevalent conditions like asthma and prostate cancer.
AARP highlights that rising prescription drug costs are one of the biggest concerns for seniors.
Beginning in 2025, the Inflation Control Act will also implement a $2,000 cap on out-of-pocket spending for seniors. This limit is expected to adjust with inflation, potentially rising to roughly $2,200 by 2027. Once this cap is reached, Medicare members won’t pay for any drugs that are covered. So, the negotiations for these 15 drugs might help reduce costs until they hit that limit.
According to CMS, around 5.3 million individuals with Medicare Part D coverage are currently on 15 different medications for conditions such as diabetes and asthma, contributing to $40.7 billion in Part D spending.
Beyond individual savings, lower drug prices could also benefit Medicare as a whole. Melis Basie, director of an advocacy group focused on affordable medications, explained that Medicare’s negotiation capabilities allow for better pricing on some of the most expensive drugs.
“Using its bargaining power, Medicare can lower drug prices, making the program more sustainable,” Basie noted, adding that it’s a vital method for regulating drug costs.
It’s worth mentioning that these Medicare negotiations are distinct from another price deal brokered by President Trump, which affects some GLP-1 drugs like Zepbound, Ozempic, and Wegovy. This earlier agreement resulted in monthly costs ranging from $245 to $350, which is a reduction compared to previous prices that were as high as $1,350.
However, under the previous agreement, Medicare enrollees would pay $245 for Wegovy and Ozempic, a lower figure than the $274 negotiated by CMS. Details on how these two pricing programs will interact haven’t been clarified, and CMS did not respond to requests for further information.
